



(12) Translation of
European patent specification

(11) NO/EP 3982956 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/436 (2006.01)
A61K 31/40 (2006.01)
A61K 31/65 (2006.01)
A61P 25/28 (2006.01)
A61P 31/04 (2006.01)
A61P 37/06 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.08.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.06.12
(86)	European Application Nr.	20823121.7
(86)	European Filing Date	2020.06.15
(87)	The European Application's Publication Date	2022.04.20
(30)	Priority	2019.06.14, US, 201962861855 P 2019.07.08, US, 201916504723 2019.09.09, US, 201916565242
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Atiba, Joshua O., C/o SoCal IP Law Group LLP 310 N. Westlake Blvd., Suite 120, Westlake Village, California 91362, USA
(72)	Inventor	Atiba, Joshua O., C/o SoCal IP Law Group LLP 310 N. Westlake Blvd., Suite 120, Westlake Village, California 91362, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	TRIPLE PHARMACEUTICAL COMPOSITION FOR PROTEINACEOUS INFECTION
(56)	References Cited:	WO-A1-2020/005977 US-A1- 2001 014 670 US-A1- 2016 045 520 US-A1- 2016 354 370 US-A1- 2017 333 469 US-B1- 10 350 226 XIN SHU-HUI ET AL: "Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy", NEUROTOXICITY RESEARCH, HARWOOD ACADEMIC PUBLISHERS, LAUSANNE, CH, vol. 34, no. 3, 7 April 2018 (2018-04-07), pages 733-748, XP036598308, ISSN: 1029-8428, DOI: 10.1007/S12640-018-9895-1 [retrieved on 2018-04-07]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV**1.**

- 5 Farmasøytisk sammensetning bestående av: et antibiotikum eller et farmasøytisk akseptabelt salt derav, hvori antibiotikumet innbefatter 100 mg minocyklin; et immunsuppressivt middel eller et farmasøytisk akseptabelt salt derav, hvor det immunsuppressive middelet innbefatter 2 mg sirolimus; et statin eller et farmasøytisk akseptabelt salt derav, hvor statinet består av 20 mg
- 10 atorvastatin; og én eller flere farmasøytisk akseptable bærere, fortynningsmidler eller eksipienter.

2.

- En farmasøytisk sammensetningen i henhold til krav 1 for anvendelse ved
- 15 behandlingen av et individ som har Alzheimers sykdom.